Charleston, SC -- (SBWIRE) -- 10/01/2013 -- The Team of advisers at Capital Equity Report are committed to bringing you stock picks that are noteworthy and priced at a great value. We work for you and we welcome any feedback you may have to offer. Have a look at: First Liberty Power Corp (OTCMKTS:FLPC), diaDexus, Inc. (OTCMKTS:DDXS), Affymax, Inc. (OTCMKTS:AFFY), Generex Biotechnology Corporation (OTCMKTS:GNBT)
First Liberty Power Corp (OTCMKTS:FLPC) decreased -3.95% and closed at $0.0146 on a traded volume of 3.91 million shares, in comparison to 4.20 million shares of average trading volume. So far this year, the stock is down over -25.79%.
The company has a total market capitalization of $6.81 million and its total outstanding shares are 466.75 million. First Liberty Power Corp., a mineral exploration company, engages in the exploration, development, mining, and refining of strategic industrial metals in the United States. Its primary target elements include lithium, antimony, vanadium, uranium, and graphite.
Why Should Investors Buy FLPC After the Recent Fall? Just Go Here and Find Out
diaDexus, Inc. (OTCMKTS:DDXS) soared +1.68% and closed at $1.82 on a traded volume of 263,267 shares, whereas its average trading volume is 261,688 shares. In the last three months, the stock is up +133.33%. The Intra-day range for the stock is $1.82 and $1.91.
diaDexus, Inc., a life sciences company, focuses on the development and commercialization of proprietary cardiovascular diagnostic products addressing needs in cardiovascular disease.
Will DDXS Continue To Move Higher? Find Out Here
Affymax, Inc. (OTCMKTS:AFFY) dropped down -0.73% and closed at $1.36. So far in three months, the stock is up +15.00%. The 52-week range for the stock is $0.78 and $27.74 and during the previous trading session the stock touched its highest price at $1.41. Its introductory price for the day was $1.36, with the overall traded volume of 285,623 shares.
Affymax, Inc., a biopharmaceutical company, engages in discovering, developing, and delivering therapies that improve the lives of patients with kidney diseases, and other serious and life-threatening illnesses.
Has AFFY Found The Bottom and Ready To Move Up? Find Out Here
Generex Biotechnology Corporation (OTCMKTS:GNBT), after opening its shares at the price of $0.03, dropped -6.80% to close at $0.0315 for the day. The stock moved on a traded volume of 5.96 million shares, in comparison to 1.72 million shares of average trading volume.
The 52-week range for the stock is $0.02 and $0.07 and during the previous trading session the stock touched its highest price at $0.03. Its introductory price for the day was $0.03. Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases.
Will GNBT Get Buyers Even After The Recent Rally? Find Out Here
Our team of advisers here at Capital Equity Report are committed to bringing you stock picks that are noteworthy and priced at a great value. We work for you and we welcome any feedback you may have to offer.
The disclaimer is to be read and fully understood before using our site, or joining our newsletter email list. Never invest into a stock discussed on this web site or the CapitalEquityReport.com newsletter unless you can afford to lose your entire investment.
Please consult with a certified financial advisor before making any investment decisions.
Read Full Disclaimer at: http://capitalequityreport.com/about-us/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)